Global X ETFs launches three new ETFs

ETF provider Global X ETFs has launched three UCITS ETFs on London Stock Exchange: the Global X U.S. Infrastructure Development UCITS ETF (PAVE), the Global X Genomics & Biotechnology UCITS ETF (GNOM), and the Global X Cloud Computing (CLO). These three funds represent Global X’s latest additions to its UCITS product line-up in Europe and showcase the firm’s continued commitment to the European market.

The new UCITS ETFs are part of Global X’s Thematic Growth family, which offers investors targeted exposure to companies around the world driving long-term, paradigm-shifting themes. The firm writes that it has established itself as the global leader in thematic investing, with 32 targeted products in the space in the US market, representing more than USD21 billion in assets under management. The new UCITS funds harness Global X’s more than a decade of experience researching, designing, and operating ETFs poised to benefit from structural shifts occurring around the globe.
“With these latest launches, we’re continuing to expand our industry-leading thematic offerings to include three additional emerging and powerful themes: an increase in infrastructure activity in the United States, further advances in the field of genomic science, and increased adoption of cloud computing technology,” says Luis Berruga, CEO of Global X. “Our focus has always been on bringing products to market that offer investors access to untapped market segments, and these three funds represent a continuation of this goal. In keeping with that sentiment, PAVE and GNOM both represent first-of-their-kind products in the European market and we’re thrilled to be bringing these strategies to investors across Europe and around the world.”

PAVE: Global X U.S. Infrastructure Development UCITS ETF

The Global X U.S. Infrastructure Development UCITS ETF (PAVE) seeks to invest in companies that stand to benefit from a potential increase in infrastructure investment in the United States including those involved in the production of raw materials, heavy equipment, engineering, and construction. PAVE follows the Indxx U.S. Infrastructure Development v2 Index. The passage of a long-awaited U.S. infrastructure spending bill would mark the start of a structural transformation of US infrastructure to meet changing societal and demographic demands, achieve net-zero emissions by 2050 as well as upgrade digital infrastructure.

PAVE has an expense ratio of 0.47 per cent.

GNOM: Global X Genomics & Biotechnology UCITS ETF

The Global X Genomics & Biotechnology ETF (GNOM), which follows the Solactive Genomics v2 Index, focuses on companies that potentially stand to benefit from further advances in the field of genomic science. Such advancements involve companies specialised in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology. Waves of private and public investment and R&D have poured into the space to further understand and treat various genetic disorders, complex diseases and medical conditions. Personalised treatments based on an individual’s unique genetic sequence would represent a monumental leap in health care, enabling people to live longer and healthier.

GNOM has an expense ratio of 0.50 per cent.

CLO: Global X Cloud Computing UCITS ETF
In today’s world where robust digital infrastructure and remote work arrangements are vital, we increasingly hear about the importance of the cloud – the virtual space where software applications run, data reside, and computing occurs. The Global X Cloud Computing UCITS ETF (CLO) seeks to invest in companies positioned to benefit from the increased adoption of cloud computing technology, including companies whose principal business is in offering computing Software-as-a-Service (SaaS), Platform-as-a-Service (PaaS), Infrastructure-as-a-Service (IaaS), managed server storage space and data centre real estate investment trusts, and/or cloud and edge computing infrastructure and hardware. CLO tracks the Indxx Global Cloud Computing v2 Index.

CLO has an expense ratio of 0.55 per cent.
 

Author Profile